In summary, SGLT2 inhibitors provide multiple benefits in individuals with T2DM and IHD, primarily via a reduction in cardiovascular death, all-cause death, and renal and hospitalisation for heart failure events. This evidence concerns the gene SLC5A2 and heart failure.